Europäische Union -
Deutsch -
EMA (European Medicines Agency)
brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastische mittel - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).
Deutschland -
Deutsch -
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
kanilad 200 mg filmtabletten
medochemie limited (3203620) - lacosamid - filmtablette - teil 1 - filmtablette; lacosamid (31188) 200 milligramm
Deutschland -
Deutsch -
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
kanilad 150 mg filmtabletten
medochemie limited (3203620) - lacosamid - filmtablette - teil 1 - filmtablette; lacosamid (31188) 150 milligramm
Deutschland -
Deutsch -
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
kanilad 100 mg filmtabletten
medochemie limited (3203620) - lacosamid - filmtablette - teil 1 - filmtablette; lacosamid (31188) 100 milligramm
Deutschland -
Deutsch -
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
kanilad 50 mg filmtabletten
medochemie limited (3203620) - lacosamid - filmtablette - teil 1 - filmtablette; lacosamid (31188) 50 milligramm
